Eli Lilly & Co. said late Friday that the U.S. Food and Drug Administration has issued an emergency-use authorization for bebtelovimab, the pharma company’s antibody treatment for COVID-19. Bebtelovimab now can be used for the treatment of mild-to-moderate COVID-19 in adults as well as children older than 12 years of age and over a certain weight who are at high risk of severe COVID-19 and for whom treatment options may be limited. Lilly announced late Thursday that the U.S. government had agreed to buy about 600,000 doses of bebtelovimab pending the EUA. Shares of Lilly were flat in the extended session after ending the regular trading day down 1.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
